UnknownPhase 3

Short-Term Versus 6-Week Prednisone in The Treatment of Subacute Thyroiditis

600 participantsStarted 2024-04-01

Plain-language summary

The goal of this clinical trial is to compare the efficacy and safety of short-term versus 6-week prednisone in the treatment of moderate-to-severe subacute thyroiditis. The main questions it aims to answer are: Does the short-term medication regimen reduce glucocorticoid side effects while achieving similar efficacy as the guideline treatment group? Patients with moderate-to-severe symptoms were randomly assigned to receive either 30 mg/day prednisone for 1 week, followed by 1 week of nonsteroidal anti-inflammatory drugs, or the conventional 6-week prednisone therapy in the control group.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * We enrolled adult patients (age 18-70) with Subacute Thyroiditis (SAT) scores ≥3 points. SAT was diagnosed on the basis of diagnostic criteria. The severity of SAT was scored as follows: fever - none, \<38℃, and \>38℃ (0, 1, and 2 points, respectively); tenderness - none, mild, and severe (0, 1, and 2 points, respectively); goiter by ultrasonography or palpation - none and yes (0 and 1 point, respectively); and ESR - normal, 25-60 mm/h, and \>60 mm/h (0, 1, and 2 points, respectively). Exclusion Criteria: * Patients who were diagnosed with diabetes, an active peptic ulcer, benign and malignant tumors, hepatic dysfunction, recurrent SAT, and already on glucocorticoid therapy were excluded within 3 months.

What they're measuring

The difference in efficacy between the two groups at the completion.

Timeframe: The palpation and CRP will investigate at 2nd (experimental group) or 6th (control group) weeks.

Trial details

NCT IDNCT06285617

SponsorXinqiao Hospital of Chongqing

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-01-31